EGFR and non-small cell lung carcinoma: Besides, previous studies also support that a considerable proportion of NSCLC patients harboring wild-type EGFR still achieve clinical benefit from gefitinib treatment (Zhou and Zhou, 2015; Shepherd, 2016).